clinical trial · NCT07218887
ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
Alexion Pharmaceuticals, Inc.·phase2·recruiting·n = 6
BAG3 Mutation Associated Dilated CardiomyopathyALXN2350
brief summary
This Phase 1/2 study is an open-label, dose finding and dose expansion study investigating the safety, tolerability, and efficacy of a single IV infusion of ALXN2350 in adult participants with BAG3 associated DCM.
started
Oct 24, 2025
primary completion
Jan 27, 2032
completion
Jan 27, 2032
last updated
Mar 4, 2026
official title
A Phase 1/2, Open-Label, Multicenter, Dose Finding and Dose Expansion Study to Investigate the Safety, Tolerability, and Efficacy of ALXN2350 Gene Therapy in Adult Participants With BAG3 Mutation Associated Dilated Cardiomyopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol